Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 127 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Reunión anual de la American Society of Clinical Oncology (ASCO) de... June 3, 2022 Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban February 7, 2022 First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer... April 21, 2022 Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of... July 23, 2024 Load more HOT NEWS High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab Girl Whose Insides Were Sucked From Her Body While Sitting On...
